InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,460.48
(
-0.41%
)
US TECH 100
19,181.60
(
-0.43%
)
Dow Jones
39,118.86
(
-0.12%
)
Brent Oil
84.85
(
0.00%
)
Bitcoin
60,826.57
(
0.85%
)
Post# of 252426
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119954
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 216504

Friday, 01/12/2018 10:25:16 AM

Friday, January 12, 2018 10:25:16 AM

Post# of 252426
ENTA—Mavyret market-share update for week ending 1/5/18 (according to IMS)…

Mavyret’s US market share among all HCV drugs was 33% for NRx (the highest it has ever been) and 26% for TRx.

(Mavyret’s NRx market share is substantially higher than its TRx market share because, unlike competing products, Mavyret’s duration is only 8 weeks for almost all patients.)

We are now 23 weeks into Mavyret’s US launch.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up